Phase 1 Trial of MLN0128 (Sapanisertib) and CB-839 HCl (Telaglenastat) in Patients With Advanced NSCLC (NCI 10327): Rationale and Study Design

Riess, JW; Frankel, P; Shackelford, D; Dunphy, M; Badawi, RD; Nardo, L; Cherry, SR; Lanza, I; Reid, J; Gonsalves, WI; Kunos, C; Gandara, DR; Lara, PN; Newman, E; Paik, PK

Riess, JW (corresponding author), UC Davis Comprehens Canc Ctr, Dept Internal Med, Div Hematol Oncol, Sacramento, CA 95817 USA.

CLINICAL LUNG CANCER, 2021; 22 (1): 67

Abstract

Introduction: There are currently no approved targeted therapies for lung squamous-cell carcinoma (LSCC) and KRAS-mutant lung adenocarcinoma (LUAD). A......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索